No Data
No Data
Bristol Myers Stock (NYSE:BMY): Perfect Place to Wait Out Market Volatility
Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ
Evotec Gets $25 Million From Bristol Myers Squibb Partnership
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment
Bristol Myers Cited by FDA for Misleading Claims on Krazati Website
No Data
103189865 : mony half widrow
103159190 : Why is McDonald's earnings forecast lower than expected and the pre-market price will rise?
104371487 On Paris : Thanks you
105535782 : ok
Captain Woon 103159190 : Market is irrational… buy on bad news
View more comments...